BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27219867)

  • 21. Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4.
    Zhang Q; Zeng L; Shen C; Ju Y; Konuma T; Zhao C; Vakoc CR; Zhou MM
    Structure; 2016 Jul; 24(7):1201-8. PubMed ID: 27291650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of 4,5-dihydro-benzodiazepinone derivatives as a new chemical series of BRD4 inhibitors.
    Li J; Wang P; Zhou B; Shi J; Liu J; Li X; Fan L; Zheng Y; Ouyang L
    Eur J Med Chem; 2016 Oct; 121():294-299. PubMed ID: 27266999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
    Blee AM; Liu S; Wang L; Huang H
    Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain.
    Bamborough P; Barnett HA; Becher I; Bird MJ; Chung CW; Craggs PD; Demont EH; Diallo H; Fallon DJ; Gordon LJ; Grandi P; Hobbs CI; Hooper-Greenhill E; Jones EJ; Law RP; Le Gall A; Lugo D; Michon AM; Mitchell DJ; Prinjha RK; Sheppard RJ; Watson AJ; Watson RJ
    ACS Med Chem Lett; 2016 Jun; 7(6):552-7. PubMed ID: 27326325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer.
    da Motta LL; Ledaki I; Purshouse K; Haider S; De Bastiani MA; Baban D; Morotti M; Steers G; Wigfield S; Bridges E; Li JL; Knapp S; Ebner D; Klamt F; Harris AL; McIntyre A
    Oncogene; 2017 Jan; 36(1):122-132. PubMed ID: 27292261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer.
    Raina K; Lu J; Qian Y; Altieri M; Gordon D; Rossi AM; Wang J; Chen X; Dong H; Siu K; Winkler JD; Crew AP; Crews CM; Coleman KG
    Proc Natl Acad Sci U S A; 2016 Jun; 113(26):7124-9. PubMed ID: 27274052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.
    Zucconi BE; Luef B; Xu W; Henry RA; Nodelman IM; Bowman GD; Andrews AJ; Cole PA
    Biochemistry; 2016 Jul; 55(27):3727-34. PubMed ID: 27332697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting BET bromodomain proteins in solid tumors.
    Sahai V; Redig AJ; Collier KA; Eckerdt FD; Munshi HG
    Oncotarget; 2016 Aug; 7(33):53997-54009. PubMed ID: 27283767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isoxazole-Derived Amino Acids are Bromodomain-Binding Acetyl-Lysine Mimics: Incorporation into Histone H4 Peptides and Histone H3.
    Sekirnik Née Measures AR; Hewings DS; Theodoulou NH; Jursins L; Lewendon KR; Jennings LE; Rooney TP; Heightman TD; Conway SJ
    Angew Chem Int Ed Engl; 2016 Jul; 55(29):8353-7. PubMed ID: 27264992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BET inhibition as a new strategy for the treatment of gastric cancer.
    Montenegro RC; Clark PG; Howarth A; Wan X; Ceroni A; Siejka P; Nunez-Alonso GA; Monteiro O; Rogers C; Gamble V; Burbano R; Brennan PE; Tallant C; Ebner D; Fedorov O; O'Neill E; Knapp S; Dixon D; Müller S
    Oncotarget; 2016 Jul; 7(28):43997-44012. PubMed ID: 27259267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue.
    Stratikopoulos EE; Parsons RE
    Clin Cancer Res; 2016 Jun; 22(11):2605-10. PubMed ID: 27250929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases.
    Padmanabhan B; Mathur S; Manjula R; Tripathi S
    J Biosci; 2016 Jun; 41(2):295-311. PubMed ID: 27240990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.
    Crawford TD; Vartanian S; Côté A; Bellon S; Duplessis M; Flynn EM; Hewitt M; Huang HR; Kiefer JR; Murray J; Nasveschuk CG; Pardo E; Romero FA; Sandy P; Tang Y; Taylor AM; Tsui V; Wang J; Wang S; Zawadzke L; Albrecht BK; Magnuson SR; Cochran AG; Stokoe D
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3534-3541. PubMed ID: 28606761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.
    Crawford TD; Romero FA; Lai KW; Tsui V; Taylor AM; de Leon Boenig G; Noland CL; Murray J; Ly J; Choo EF; Hunsaker TL; Chan EW; Merchant M; Kharbanda S; Gascoigne KE; Kaufman S; Beresini MH; Liao J; Liu W; Chen KX; Chen Z; Conery AR; Côté A; Jayaram H; Jiang Y; Kiefer JR; Kleinheinz T; Li Y; Maher J; Pardo E; Poy F; Spillane KL; Wang F; Wang J; Wei X; Xu Z; Xu Z; Yen I; Zawadzke L; Zhu X; Bellon S; Cummings R; Cochran AG; Albrecht BK; Magnuson S
    J Med Chem; 2016 Dec; 59(23):10549-10563. PubMed ID: 27682507
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic backgrounds and modifier genes of NTD mouse models: An opportunity for greater understanding of the multifactorial etiology of neural tube defects.
    Leduc RY; Singh P; McDermid HE
    Birth Defects Res; 2017 Jan; 109(2):140-152. PubMed ID: 27768235
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains.
    Karim RM; Chan A; Zhu JY; Schönbrunn E
    J Med Chem; 2020 Mar; 63(6):3227-3237. PubMed ID: 32091206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.
    Bauer N; Balourdas DI; Schneider JR; Zhang X; Berger LM; Berger BT; Schwalm MP; Klopp NA; Siveke JT; Knapp S; Joerger AC
    ACS Chem Biol; 2024 Feb; 19(2):266-279. PubMed ID: 38291964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reevaluation of bromodomain ligands targeting BAZ2A.
    Cazzanelli G; Vedove AD; Parolin E; D'Agostino VG; Unzue A; Nevado C; Caflisch A; Lolli G
    Protein Sci; 2023 Sep; 32(9):e4752. PubMed ID: 37574751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deciphering Selectivity Mechanism of BRD9 and TAF1(2) toward Inhibitors Based on Multiple Short Molecular Dynamics Simulations and MM-GBSA Calculations.
    Wang L; Wang Y; Yu Y; Liu D; Zhao J; Zhang L
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.